{"protocolSection": {"identificationModule": {"nctId": "NCT01631864", "orgStudyIdInfo": {"id": "CLCZ696B2207"}, "secondaryIdInfos": [{"id": "2012-002606-40", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects", "officialTitle": "A Randomized, Double-blind, Parallel Group Study to Evaluate Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects"}, "statusModule": {"statusVerifiedDate": "2015-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-10"}, "primaryCompletionDateStruct": {"date": "2013-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-06-27", "studyFirstSubmitQcDate": "2012-06-28", "studyFirstPostDateStruct": {"date": "2012-06-29", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-07-11", "resultsFirstSubmitQcDate": "2015-07-11", "resultsFirstPostDateStruct": {"date": "2015-08-10", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-07-11", "lastUpdatePostDateStruct": {"date": "2015-08-10", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study investigated the effects of LCZ696 on insulin sensitivity, lipolysis, and oxidative metabolism in obese hypertensive subjects."}, "conditionsModule": {"conditions": ["Hypertension", "Concurrent Obesity"], "keywords": ["Hypertension, obesity, insulin sensitivity, lipolysis, LCZ696"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 98, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "LCZ696", "type": "EXPERIMENTAL", "description": "LCZ696 400 mg plus placebo to amlodipine once daily for 8 weeks", "interventionNames": ["Drug: LCZ696", "Drug: Placebo"]}, {"label": "amlodipine", "type": "ACTIVE_COMPARATOR", "description": "amlodipine 10 mg plus placebo to LCZ696 once daily for 8 weeks", "interventionNames": ["Drug: amlodipine", "Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "LCZ696", "description": "LCZ696 was provided as 400 mg tablets.", "armGroupLabels": ["LCZ696"]}, {"type": "DRUG", "name": "amlodipine", "description": "amlodipine was provided as 5 mg tablets.", "armGroupLabels": ["amlodipine"]}, {"type": "DRUG", "name": "Placebo", "description": "Matching placebo to LCZ696 and amlodipine.", "armGroupLabels": ["LCZ696", "amlodipine"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Insulin Sensitivity Index", "description": "The insulin sensitivity index was assessed by hyperinsulinemic euglycemic clamp (HEGC). A positive change from baseline indicates improvement.", "timeFrame": "baseline, 8 weeks"}], "secondaryOutcomes": [{"measure": "Local Adipose Tissue Lipolysis, Glycerol Concentrations", "description": "Lipolysis was assessed through subcutaneous adipose tissue microdialysis. The actual measure type is adjusted geometric mean.", "timeFrame": "57 days"}, {"measure": "Oxidative Metabolism", "description": "Oxidative metabolism was assessed by indirect calorimetry.", "timeFrame": "57 days"}, {"measure": "Number of Participants With Adverse Events, Serious Adverse Events and Deaths", "description": "Adverse event monitoring was conducted throughout the study.", "timeFrame": "8 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Written informed consent must be obtained before any study assessment is performed.\n* Males and females of non-childbearing potential \u2265 18 years of age.\n* Subjects with mild to moderate essential hypertension,\n\n  * Untreated subjects must have a mean seated SBP (msSBP) \u2265 130 mmHg and \\< 180 mmHg at screening.\n  * Pre-treated subjects must have a msSBP \u2264 160 mmHg at screening and \\< 180 mmHg at the end of the washout period.\n* Waist circumference \u2265 102 cm (men) and \u2265 88 cm (women);\n\nExclusion criteria:\n\n* Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer; or longer if required by local regulations.\n* History of angioedema, drug-related or otherwise\n* History of hypersensitivity to LCZ696, amlodipine, or drugs of similar chemical classes.\n* Severe hypertension (grade 3 of WHO classification; msDBP \u2265100 mmHg and/or msSBP \u2265 180 mmHg) at screening or at the end of the washout period.\n* Type 1 or Type 2 diabetes mellitus.\n* Dyslipidemia requiring pharmacological therapy with a fibrate or nicotinic acid.\n* Concomitant use of anti-hypertensives, anti-diabetics, or drugs with effects on glucose or lipid metabolism for the duration of the study.\n\nOther protocol defined inclusion/exclusion criteria may apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Hannover", "zip": "30625", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}, {"facility": "Novartis Investigative Site", "city": "Neuss", "zip": "41460", "country": "Germany", "geoPoint": {"lat": 51.19807, "lon": 6.68504}}, {"facility": "Novartis Investigative Site", "city": "Maastricht", "zip": "5800", "country": "Netherlands", "geoPoint": {"lat": 50.84833, "lon": 5.68889}}]}, "referencesModule": {"references": [{"pmid": "29180454", "type": "DERIVED", "citation": "Engeli S, Stinkens R, Heise T, May M, Goossens GH, Blaak EE, Havekes B, Jax T, Albrecht D, Pal P, Tegtbur U, Haufe S, Langenickel TH, Jordan J. Effect of Sacubitril/Valsartan on Exercise-Induced Lipid Metabolism in Patients With Obesity and Hypertension. Hypertension. 2018 Jan;71(1):70-77. doi: 10.1161/HYPERTENSIONAHA.117.10224. Epub 2017 Nov 27."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "LCZ696", "description": "LCZ696 400 mg plus placebo to amlodipine once daily for 8 weeks"}, {"id": "FG001", "title": "Amlodipine", "description": "amlodipine 10 mg plus placebo to LCZ696 once daily for 8 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "50"}, {"groupId": "FG001", "numSubjects": "48"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "48"}, {"groupId": "FG001", "numSubjects": "44"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "4"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "LCZ696", "description": "LCZ696 400 mg plus placebo to amlodipine once daily for 8 weeks"}, {"id": "BG001", "title": "Amlodipine", "description": "amlodipine 10 mg plus placebo to LCZ696 once daily for 8 weeks"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "50"}, {"groupId": "BG001", "value": "48"}, {"groupId": "BG002", "value": "98"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "51.9", "spread": "9.6"}, {"groupId": "BG001", "value": "50.5", "spread": "9.4"}, {"groupId": "BG002", "value": "51.2", "spread": "9.5"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "22"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "41"}, {"groupId": "BG001", "value": "35"}, {"groupId": "BG002", "value": "76"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Insulin Sensitivity Index", "description": "The insulin sensitivity index was assessed by hyperinsulinemic euglycemic clamp (HEGC). A positive change from baseline indicates improvement.", "populationDescription": "Pharmacodynamic Analysis Set (PDS): Only participants from the PDS, who had both baseline and day 56 values, were included in the analysis. The PDS included all randomized participants who received at least one dose of study drug and had no protocol deviations with relevant impact on PD data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "ug/kg*min/(mmol/L*pmol/L)", "timeFrame": "baseline, 8 weeks", "groups": [{"id": "OG000", "title": "LCZ696", "description": "LCZ696 400 mg plus placebo to amlodipine once daily for 8 weeks"}, {"id": "OG001", "title": "Amlodipine", "description": "amlodipine 10 mg plus placebo to LCZ696 once daily for 8 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "41"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.192", "lowerLimit": "0.025", "upperLimit": "0.359"}, {"groupId": "OG001", "value": "0.065", "lowerLimit": "-0.0116", "upperLimit": "0.246"}]}]}]}, {"type": "SECONDARY", "title": "Local Adipose Tissue Lipolysis, Glycerol Concentrations", "description": "Lipolysis was assessed through subcutaneous adipose tissue microdialysis. The actual measure type is adjusted geometric mean.", "populationDescription": "Pharmacodynamic Analysis Set (PDS): Only participants from the PDS, who had both baseline and day 56 values, were included in the analysis. The PDS included all randomized participants who received at least one dose of study drug and had no protocol deviations with relevant impact on PD data.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "micro mol/L", "timeFrame": "57 days", "groups": [{"id": "OG000", "title": "LCZ696", "description": "LCZ696 400 mg plus placebo to amlodipine once daily for 8 weeks"}, {"id": "OG001", "title": "Amlodipine", "description": "amlodipine 10 mg plus placebo to LCZ696 once daily for 8 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "47"}, {"groupId": "OG001", "value": "42"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "82.46", "lowerLimit": "74.53", "upperLimit": "91.23"}, {"groupId": "OG001", "value": "65.91", "lowerLimit": "59.22", "upperLimit": "73.37"}]}]}]}, {"type": "SECONDARY", "title": "Oxidative Metabolism", "description": "Oxidative metabolism was assessed by indirect calorimetry.", "populationDescription": "Pharmacodynamic Analysis Set (PDS): Only participants from the PDS, who had both baseline and day 56 values, were included in the analysis. The PDS included all randomized participants who received at least one dose of study drug and had no protocol deviations with relevant impact on PD data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "carbon dioxide to oxygen ratio", "timeFrame": "57 days", "groups": [{"id": "OG000", "title": "LCZ696", "description": "LCZ696 400 mg plus placebo to amlodipine once daily for 8 weeks"}, {"id": "OG001", "title": "Amlodipine", "description": "amlodipine 10 mg plus placebo to LCZ696 once daily for 8 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "40"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.787", "lowerLimit": "0.760", "upperLimit": "0.814"}, {"groupId": "OG001", "value": "0.775", "lowerLimit": "0.746", "upperLimit": "0.804"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Adverse Events, Serious Adverse Events and Deaths", "description": "Adverse event monitoring was conducted throughout the study.", "populationDescription": "Safety Analysis Set (SAS): The SAS included all randomized participants who received at least one dose of study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "LCZ696", "description": "LCZ696 400 mg plus placebo to amlodipine once daily for 8 weeks"}, {"id": "OG001", "title": "Amlodipine", "description": "amlodipine 10 mg plus placebo to LCZ696 once daily for 8 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "48"}]}], "classes": [{"title": "Adverse events (serious and non-serious)", "categories": [{"measurements": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "37"}]}]}, {"title": "Serious adverse events", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Deaths", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "LCZ696", "description": "LCZ696 400 mg plus placebo to Amlodipine once daily for 8 weeks", "seriousNumAffected": 1, "seriousNumAtRisk": 50, "otherNumAffected": 23, "otherNumAtRisk": 50}, {"id": "EG001", "title": "Amlodipine", "description": "Amlodipine 10 mg plus placebo to LCZ696 once daily for 8 weeks", "seriousNumAffected": 1, "seriousNumAtRisk": 48, "otherNumAffected": 26, "otherNumAtRisk": 48}], "seriousEvents": [{"term": "RUPTURED CEREBRAL ANEURYSM", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 50}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 48}]}, {"term": "NEPHROLITHIASIS", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 50}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}], "otherEvents": [{"term": "DIARRHOEA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 50}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "OEDEMA PERIPHERAL", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 50}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 48}]}, {"term": "NASOPHARYNGITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 50}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 48}]}, {"term": "DIZZINESS", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 50}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "HEADACHE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 50}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 48}]}, {"term": "PRURITUS", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 50}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 48}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M12701", "name": "Obesity", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "C000549068", "term": "Sacubitril and valsartan sodium hydrate drug combination"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "relevance": "LOW"}, {"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "relevance": "LOW"}, {"id": "M350410", "name": "Sacubitril and valsartan sodium hydrate drug combination", "asFound": "Pea", "relevance": "HIGH"}, {"id": "M301", "name": "Valsartan", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}]}}, "hasResults": true}